Further validation of the efficacy of mesenchymal stem cell infusions for reducing mortality in COVID-19 patients with ARDS

Recent double-blind, randomized, controlled trials reported that human umbilical cord-derived mesenchymal stem cell (MSC) infusions in COVID-19 patients with acute respiratory distress syndrome (ARDS) could diminish cytokine storm and lung damage. While these outcomes are significant, additional pha...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ashok K. Shetty, Padmashri A. Shetty, Gabriele Zanirati, Kunlin Jin
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R
Acceso en línea:	https://doaj.org/article/f9ac2c2e383640f791789acba4296424
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f9ac2c2e383640f791789acba4296424
record_format	dspace
spelling	oai:doaj.org-article:f9ac2c2e383640f791789acba42964242021-12-02T17:19:43ZFurther validation of the efficacy of mesenchymal stem cell infusions for reducing mortality in COVID-19 patients with ARDS10.1038/s41536-021-00161-z2057-3995https://doaj.org/article/f9ac2c2e383640f791789acba42964242021-09-01T00:00:00Zhttps://doi.org/10.1038/s41536-021-00161-zhttps://doaj.org/toc/2057-3995Recent double-blind, randomized, controlled trials reported that human umbilical cord-derived mesenchymal stem cell (MSC) infusions in COVID-19 patients with acute respiratory distress syndrome (ARDS) could diminish cytokine storm and lung damage. While these outcomes are significant, additional phase II/III trials are required to validate the efficacy of MSCs to improve the survival of COVID-19 patients with ARDS. Future studies also need to assess the efficacy of MSCs to prevent long COVID.Ashok K. ShettyPadmashri A. ShettyGabriele ZaniratiKunlin JinNature PortfolioarticleMedicineRENnpj Regenerative Medicine, Vol 6, Iss 1, Pp 1-3 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R
spellingShingle	Medicine R Ashok K. Shetty Padmashri A. Shetty Gabriele Zanirati Kunlin Jin Further validation of the efficacy of mesenchymal stem cell infusions for reducing mortality in COVID-19 patients with ARDS
description	Recent double-blind, randomized, controlled trials reported that human umbilical cord-derived mesenchymal stem cell (MSC) infusions in COVID-19 patients with acute respiratory distress syndrome (ARDS) could diminish cytokine storm and lung damage. While these outcomes are significant, additional phase II/III trials are required to validate the efficacy of MSCs to improve the survival of COVID-19 patients with ARDS. Future studies also need to assess the efficacy of MSCs to prevent long COVID.
format	article
author	Ashok K. Shetty Padmashri A. Shetty Gabriele Zanirati Kunlin Jin
author_facet	Ashok K. Shetty Padmashri A. Shetty Gabriele Zanirati Kunlin Jin
author_sort	Ashok K. Shetty
title	Further validation of the efficacy of mesenchymal stem cell infusions for reducing mortality in COVID-19 patients with ARDS
title_short	Further validation of the efficacy of mesenchymal stem cell infusions for reducing mortality in COVID-19 patients with ARDS
title_full	Further validation of the efficacy of mesenchymal stem cell infusions for reducing mortality in COVID-19 patients with ARDS
title_fullStr	Further validation of the efficacy of mesenchymal stem cell infusions for reducing mortality in COVID-19 patients with ARDS
title_full_unstemmed	Further validation of the efficacy of mesenchymal stem cell infusions for reducing mortality in COVID-19 patients with ARDS
title_sort	further validation of the efficacy of mesenchymal stem cell infusions for reducing mortality in covid-19 patients with ards
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/f9ac2c2e383640f791789acba4296424
work_keys_str_mv	AT ashokkshetty furthervalidationoftheefficacyofmesenchymalstemcellinfusionsforreducingmortalityincovid19patientswithards AT padmashriashetty furthervalidationoftheefficacyofmesenchymalstemcellinfusionsforreducingmortalityincovid19patientswithards AT gabrielezanirati furthervalidationoftheefficacyofmesenchymalstemcellinfusionsforreducingmortalityincovid19patientswithards AT kunlinjin furthervalidationoftheefficacyofmesenchymalstemcellinfusionsforreducingmortalityincovid19patientswithards
_version_	1718381060644929536

Further validation of the efficacy of mesenchymal stem cell infusions for reducing mortality in COVID-19 patients with ARDS

Ejemplares similares